-
1
-
-
50549174560
-
The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
-
Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 1961, 13:346-353.
-
(1961)
J. Chronic Dis.
, vol.13
, pp. 346-353
-
-
Gehan, E.A.1
-
2
-
-
0018596257
-
Predictive probability early termination plans for phase II clinical trials
-
Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979, 35:775-783.
-
(1979)
Biometrics
, vol.35
, pp. 775-783
-
-
Herson, J.1
-
3
-
-
0020108590
-
One-sample multiple testing procedure for phase II clinical trials
-
Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
-
(1982)
Biometrics
, vol.38
, pp. 143-151
-
-
Fleming, T.R.1
-
4
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989, 10:1-10.
-
(1989)
Control. Clin. Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
6
-
-
0037461309
-
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment
-
Ravina B.M., Fagan S., Hart R.G., Murphy D., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003, 60:1234-1240.
-
(2003)
Neurology
, vol.60
, pp. 1234-1240
-
-
Ravina, B.M.1
Fagan, S.2
Hart, R.G.3
Murphy, D.4
Marler, J.R.5
-
7
-
-
34147164484
-
Neuroprotection in Parkinson's disease: an elusive goal
-
Biglan K.M., Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Semin. Neurol. 2007, 2:106-112.
-
(2007)
Semin. Neurol.
, vol.2
, pp. 106-112
-
-
Biglan, K.M.1
Ravina, B.2
-
8
-
-
53449089266
-
Neuroprotection in Parkinson's disease: myth or reality?
-
Voss T., Ravina B. Neuroprotection in Parkinson's disease: myth or reality?. Curr. Neurol. Neurosci. Rep. 2008, 8(4):304-309.
-
(2008)
Curr. Neurol. Neurosci. Rep.
, vol.8
, Issue.4
, pp. 304-309
-
-
Voss, T.1
Ravina, B.2
-
9
-
-
67651160657
-
Neuroprotection trials in Parkinson's disease: systematic review
-
Hart R.G., Pearce L.A., Ravina B.M., Yaltho T.C., Marler J.R. Neuroprotection trials in Parkinson's disease: systematic review. Mov. Disord. 2009, 24(5):647-654.
-
(2009)
Mov. Disord.
, vol.24
, Issue.5
, pp. 647-654
-
-
Hart, R.G.1
Pearce, L.A.2
Ravina, B.M.3
Yaltho, T.C.4
Marler, J.R.5
-
10
-
-
0028783948
-
Tissue plasminogen activator for acute ischemic stroke
-
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333:1581-1588.
-
(1995)
N. Engl. J. Med.
, vol.333
, pp. 1581-1588
-
-
-
11
-
-
80052809265
-
Neuroprotective effects of creatine
-
Beal M.F. Neuroprotective effects of creatine. Amino Acids 2011, 40(5):1305-1313.
-
(2011)
Amino Acids
, vol.40
, Issue.5
, pp. 1305-1313
-
-
Beal, M.F.1
-
12
-
-
0022787429
-
Calibrated phase II clinical trials in oncology
-
Herson J., Carter S.K. Calibrated phase II clinical trials in oncology. Stat. Med. 1986, 5:441-447.
-
(1986)
Stat. Med.
, vol.5
, pp. 441-447
-
-
Herson, J.1
Carter, S.K.2
-
13
-
-
19944433460
-
A responsive outcome for Parkinson's disease neuroprotection futility studies
-
Elm J.J., Goetz C.G., Ravina B., Shannon K., Wooten G.F., Tanner C.M., for the NET-PD Investigators, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann. Neurol. 2005, 57(2):197-203.
-
(2005)
Ann. Neurol.
, vol.57
, Issue.2
, pp. 197-203
-
-
Elm, J.J.1
Goetz, C.G.2
Ravina, B.3
Shannon, K.4
Wooten, G.F.5
Tanner, C.M.6
-
14
-
-
33645864949
-
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs
-
Tilley B.C., Palesch Y.Y., Kieburtz K., Ravina B., Huang P., Elm J.J., for the NET-PD Investigators, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006, 66(5):628-633.
-
(2006)
Neurology
, vol.66
, Issue.5
, pp. 628-633
-
-
Tilley, B.C.1
Palesch, Y.Y.2
Kieburtz, K.3
Ravina, B.4
Huang, P.5
Elm, J.J.6
-
15
-
-
33645894705
-
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
-
NINDS NET-PD Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006, 66(5):664-671.
-
(2006)
Neurology
, vol.66
, Issue.5
, pp. 664-671
-
-
-
16
-
-
44649153832
-
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results
-
NINDS NET-PD Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 2008, 31(3):141-150.
-
(2008)
Clin. Neuropharmacol.
, vol.31
, Issue.3
, pp. 141-150
-
-
-
17
-
-
27644481285
-
Applying a phase II futility study design to therapeutic stroke trials
-
Palesch Y.Y., Tilley B.C., Sackett D.L., Johnston K.C., Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke 2005, 36(11):2410-2414.
-
(2005)
Stroke
, vol.36
, Issue.11
, pp. 2410-2414
-
-
Palesch, Y.Y.1
Tilley, B.C.2
Sackett, D.L.3
Johnston, K.C.4
Woolson, R.5
-
18
-
-
33744797087
-
Lessons from adult stroke trials
-
Pavlakis S.G., Sacco R., Levine S.R., Meschia J.F., Palesch Y., Tilley B.C., et al. Lessons from adult stroke trials. Pediatr. Neurol. 2006, 34(6):446-449.
-
(2006)
Pediatr. Neurol.
, vol.34
, Issue.6
, pp. 446-449
-
-
Pavlakis, S.G.1
Sacco, R.2
Levine, S.R.3
Meschia, J.F.4
Palesch, Y.5
Tilley, B.C.6
-
19
-
-
33846641246
-
Screening potential therapies: lessons learned from new paradigms used in Parkinson disease
-
Tilley B.C., Galpern W.R. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke 2007, 38(2 Suppl.):800-803.
-
(2007)
Stroke
, vol.38
, Issue.2
, pp. 800-803
-
-
Tilley, B.C.1
Galpern, W.R.2
-
21
-
-
33845430355
-
The value of database controls in pilot or futility studies in ALS
-
Czaplinski A., Haverkamp L.J., Yen A.A., Simpson E.P., Lai E.C., Appel S.H. The value of database controls in pilot or futility studies in ALS. Neurology 2006, 67(10):1827-1832.
-
(2006)
Neurology
, vol.67
, Issue.10
, pp. 1827-1832
-
-
Czaplinski, A.1
Haverkamp, L.J.2
Yen, A.A.3
Simpson, E.P.4
Lai, E.C.5
Appel, S.H.6
-
23
-
-
70450180994
-
Prognostic factors in ALS: a critical review
-
Chiò A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B.G., Eurals Consortium Prognostic factors in ALS: a critical review. Amyotroph. Lateral Scler. 2009, 10(5-6):310-323.
-
(2009)
Amyotroph. Lateral Scler.
, vol.10
, Issue.5-6
, pp. 310-323
-
-
Chiò, A.1
Logroscino, G.2
Hardiman, O.3
Swingler, R.4
Mitchell, D.5
Beghi, E.6
Traynor, B.G.7
-
24
-
-
78649369122
-
A futility study of minocycline in Huntington's disease
-
The Huntington Study Group DOMINO Investigators A futility study of minocycline in Huntington's disease. Mov. Disord. 2010, 25(13):2219-2224.
-
(2010)
Mov. Disord.
, vol.25
, Issue.13
, pp. 2219-2224
-
-
-
25
-
-
79957621566
-
Milestones in movement disorders clinical trials: advances and landmark studies
-
Olanow C.W., Wunderle K.B., Kieburtz K. Milestones in movement disorders clinical trials: advances and landmark studies. Mov. Disord. 2011, 26(6):1003-1014.
-
(2011)
Mov. Disord.
, vol.26
, Issue.6
, pp. 1003-1014
-
-
Olanow, C.W.1
Wunderle, K.B.2
Kieburtz, K.3
-
26
-
-
84980052961
-
Advances in designs for Alzheimer's disease clinical trials
-
Cummings J., Gould H., Zhong K. Advances in designs for Alzheimer's disease clinical trials. Am. J. Neurodegener. Dis. 2012, 1(3):205-216.
-
(2012)
Am. J. Neurodegener. Dis.
, vol.1
, Issue.3
, pp. 205-216
-
-
Cummings, J.1
Gould, H.2
Zhong, K.3
-
27
-
-
27644532415
-
The utility of futility
-
Levin B. The utility of futility. Stroke 2005, 36:2331-2332.
-
(2005)
Stroke
, vol.36
, pp. 2331-2332
-
-
Levin, B.1
-
28
-
-
33744981624
-
Issues in neuroprotection clinical trials in Parkinson's disease
-
Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology 2006, 66(10 Suppl. 4):S50-S57.
-
(2006)
Neurology
, vol.66
, Issue.10
, pp. S50-S57
-
-
Kieburtz, K.1
-
29
-
-
33645864950
-
Futility studies: spending a little to save a lot
-
Schwid S.R., Cutter G.R. Futility studies: spending a little to save a lot. Neurology 2006, 66(5):626-627.
-
(2006)
Neurology
, vol.66
, Issue.5
, pp. 626-627
-
-
Schwid, S.R.1
Cutter, G.R.2
-
31
-
-
34447301510
-
Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
-
Hung A.Y., Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Curr. Opin. Neurol. 2007, 20(4):477-483.
-
(2007)
Curr. Opin. Neurol.
, vol.20
, Issue.4
, pp. 477-483
-
-
Hung, A.Y.1
Schwarzschild, M.A.2
-
32
-
-
84867693278
-
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1
-
Elm J.J., for the NINDS NET-PD Investigators Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov. Disord. 2012, 27(12):1513-1521.
-
(2012)
Mov. Disord.
, vol.27
, Issue.12
, pp. 1513-1521
-
-
Elm, J.J.1
-
33
-
-
84885177997
-
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods
-
Yeatts S.D., Palesch Y.Y., Moy C.S., Selim M. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit. Care 2013, 19(2):257-266.
-
(2013)
Neurocrit. Care
, vol.19
, Issue.2
, pp. 257-266
-
-
Yeatts, S.D.1
Palesch, Y.Y.2
Moy, C.S.3
Selim, M.4
-
34
-
-
84882375832
-
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial
-
Lewis R.A., McDermott M.P., Herrmann D.N., Hoke A., Clawson L.L., Siskind C., et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013, 70(8):981-987.
-
(2013)
JAMA Neurol.
, vol.70
, Issue.8
, pp. 981-987
-
-
Lewis, R.A.1
McDermott, M.P.2
Herrmann, D.N.3
Hoke, A.4
Clawson, L.L.5
Siskind, C.6
-
35
-
-
84880282982
-
Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans
-
Moore C.G., Schenkman M., Kohrt W.M., Delitto A., Hall D.A., Corcos D. Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. Contemp. Clin. Trials 2013, 36(1):90-98.
-
(2013)
Contemp. Clin. Trials
, vol.36
, Issue.1
, pp. 90-98
-
-
Moore, C.G.1
Schenkman, M.2
Kohrt, W.M.3
Delitto, A.4
Hall, D.A.5
Corcos, D.6
-
36
-
-
33645852575
-
A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
-
Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006, 66:660-663.
-
(2006)
Neurology
, vol.66
, pp. 660-663
-
-
Levy, G.1
Kaufmann, P.2
Buchsbaum, R.3
Montes, J.4
Barsdorf, A.5
Arbing, R.6
-
37
-
-
70249116820
-
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
-
Kaufmann P., Thompson J.L.P., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., for the QALS Study Group, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009, 66:235-244.
-
(2009)
Ann. Neurol.
, vol.66
, pp. 235-244
-
-
Kaufmann, P.1
Thompson, J.L.P.2
Levy, G.3
Buchsbaum, R.4
Shefner, J.5
Krivickas, L.S.6
-
38
-
-
84870889573
-
Selection and futility designs. Chapter 8
-
Cambridge University Press, Cambridge, B. Ravina, J. Cummings, M.P. McDermott, M. Poole (Eds.)
-
Levin B. Selection and futility designs. Chapter 8. Clinical Trials in Neurology 2012, Cambridge University Press, Cambridge. B. Ravina, J. Cummings, M.P. McDermott, M. Poole (Eds.).
-
(2012)
Clinical Trials in Neurology
-
-
Levin, B.1
-
39
-
-
84880310048
-
Novel methodologic approaches to phase I, II, and III trials
-
Yeatts S.D. Novel methodologic approaches to phase I, II, and III trials. Stroke 2013, 44(6 Suppl. 1):S116-S118.
-
(2013)
Stroke
, vol.44
, Issue.6
, pp. S116-S118
-
-
Yeatts, S.D.1
-
40
-
-
84889859929
-
Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials?
-
Sackett D.L. Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials?. Clin. Trials 2013, 10(6):987-989.
-
(2013)
Clin. Trials
, vol.10
, Issue.6
, pp. 987-989
-
-
Sackett, D.L.1
-
41
-
-
84929281003
-
The promise of futility trials in neurological diseases
-
(epub ahead of print)
-
Koch M.W., Korngut L., Patry D.G., Agha-Khani Y., White C., Sarna J.R., et al. The promise of futility trials in neurological diseases. Nat. Rev. Neurol. 2015, (epub ahead of print). 10.1038/nrneurol.2015.34.
-
(2015)
Nat. Rev. Neurol.
-
-
Koch, M.W.1
Korngut, L.2
Patry, D.G.3
Agha-Khani, Y.4
White, C.5
Sarna, J.R.6
-
42
-
-
84893488628
-
Clinical trials in multiple sclerosis. Chap 20
-
Cutter G., Kappos L. Clinical trials in multiple sclerosis. Chap 20. Handbook of Clinical Neurology 2014, 122(3rd series):445-453.
-
(2014)
Handbook of Clinical Neurology
, pp. 445-453
-
-
Cutter, G.1
Kappos, L.2
-
43
-
-
0027530638
-
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
-
The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 1993, 328:176-183.
-
(1993)
N. Engl. J. Med.
, vol.328
, pp. 176-183
-
-
-
44
-
-
33645894705
-
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease
-
NINDS NET-PD Investigators A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2006, 66:664-671.
-
(2006)
Neurology
, vol.66
, pp. 664-671
-
-
-
45
-
-
84924034345
-
Problems with constructing tests to accept the null hypothesis
-
Chap 4 in. Interdisciplinary Bayesian Statistics
-
Rogatko A., Piantadosi S. Problems with constructing tests to accept the null hypothesis. Springer Proc in Math & Stat 2015, 118:49-54.
-
(2015)
Springer Proc in Math & Stat
, vol.118
, pp. 49-54
-
-
Rogatko, A.1
Piantadosi, S.2
|